Clinical trials
Breast Cancer Invasive clinical trials
Below are recruiting breast cancer invasive clinical trials, each written for real people, not researchers. We’re tracking 717 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07137416RecruitingPhase 1
Combination drug study for HER2-positive breast and other cancers
This study tests a new combination of two anti-cancer drugs (CX-5461 and T-DXd) for people with HER2-positive breast cancer or other solid tumors. It aims to see if the combination is safe and how well it works.
Boston, MassachusettsAges 18 years+ - NCT07619534Recruiting
Collecting Spinal Fluid from Advanced Breast Cancer Patients
This study collects spinal fluid samples from people with advanced (metastatic) HER2-positive or triple-negative breast cancer who have never had, and currently do not have, cancer spread to the brain. Researchers want to understand how cancer cells might reach the nervous system and develop better treatments.
Bethesda, MarylandAges 18–120 - NCT06633276Recruiting
Fast gene test for breast cancer diagnosis in Tanzania
This trial tests a new, fast method to diagnose breast cancer using a gene sequencing technique called nanopore sequencing. It aims to give accurate results quickly from a tumor sample taken during a biopsy or surgery.
MoshiAges 18 years+ - NCT07391774RecruitingPhase 3
Hormone therapy with or without chemo for early breast cancer
This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.
Jonesboro, ArkansasAges 18 years+ - NCT04665882Recruiting
Prediction tool for arm swelling after breast cancer surgery
This trial tests a prediction tool (a “nomogram”) to estimate who is at risk of developing breast cancer–related lymphedema, or long-term arm swelling, after surgery. If you fit the surgery and lymph node criteria, your information may help personalize follow-up and prevention.
Wuhan, HubeiAges 18–80 - NCT03787056Recruiting
Blood test marker study in many cancer types
This study measures a blood marker called progastrin (at diagnosis and during treatment) to see how well it predicts response or outcomes. It may help doctors choose or monitor treatment more precisely for several cancer types.
BronAges 18 years+ - NCT05059379RecruitingPhase 3
Different radiation fields after breast cancer surgery
This trial compares two ways of giving radiation to lymph node areas near the collarbone after surgery for invasive breast cancer. It aims to see which radiation approach works better and is safer for preventing cancer returning in these lymph nodes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT02535221RecruitingPhase 3
Hormone treatment vs chemotherapy before breast surgery
This Phase 3 trial compares hormone-based treatment versus chemotherapy given before surgery in people who are premenopausal and have hormone-receptor positive, HER2-negative breast cancer. It looks to see which approach works better to control the cancer before the breast operation.
BeijingAges 35–55 - NCT05292742RecruitingPhase 2
Continue targeted breast cancer therapy or switch to a new combo
This Phase 2 study compares two treatment plans after breast surgery when cancer did not fully disappear before surgery. It tests whether adding trastuzumab, pyrotinib, and capecitabine works better than continuing the original targeted therapy.
Fuzhou, FujianAges 18–75 - NCT04836156RecruitingPhase 1/Phase 2
Personalized pre-surgery treatment for HER2-negative early breast cancer
This study tests a treatment plan chosen using lab drug testing on a patient’s tumor (in a dish). It may help improve outcomes for people with early breast cancer that is HER2-negative by matching therapy to what the tumor seems sensitive to.
BeijingAges 18–75 - NCT05420454RecruitingPhase 4
Neoadjuvant treatment for breast cancer before surgery
This trial tests a treatment given before breast surgery to shrink breast cancer and improve outcomes based on your tumor type. Your eligibility depends on tumor size/stage, hormone and HER2 markers, and overall health checks.
Hangzhou, ZhejiangAges 18 years+ - NCT04698252RecruitingPhase 2
Local treatment for ER/PR-positive limited spread breast cancer
This Phase 2 study tests whether treating a small number of metastatic spots with a local approach (like targeted radiation, surgery, or ablation) can help people with ER/PR-positive breast cancer. It aims to help when the cancer has spread only to a few areas and has not significantly worsened after initial whole-body treatment.
São Paulo, São PauloAges 18 years+ - NCT04486495Recruiting
Minimally invasive lymph node treatment after chemo for node-positive breast cancer
This study looks at a less invasive way to check and treat lymph nodes in the armpit after you receive chemotherapy (and sometimes immunotherapy) before breast surgery. It may help people with cancer that has already spread to armpit lymph nodes by improving how staging and treatment are done.
's-HertogenboschAges 18 years+ - NCT03150576RecruitingPhase 2/Phase 3
Before-surgery treatment for triple-negative or BRCA breast cancer
This trial tests an “at-the-source” medicine given before surgery to shrink triple-negative and/or BRCA-related breast cancer. It may help doctors see whether it improves tumor response and reduces cancer spread at surgery time.
Cambridge, CambridgeshireAges 16–70 - NCT05462457Recruiting
Tests adding a targeted approach for breast cancer with many involved nodes
This trial studies a treatment plan for early breast cancer that involves at least three suspicious lymph nodes on the ultrasound/imaging. It looks at whether a targeted technique—done before surgery with chemotherapy—can improve or guide care when surgery will remove the lymph nodes.
EssenAges 18 years+ - NCT05833659Recruiting
Comparing two breast reconstruction positions after mastectomy
This trial compares two surgical techniques for breast reconstruction: placing the implant under the chest muscle versus in front of it. It may help people understand which approach works better for comfort and healing after mastectomy.
Beijing, Beijing MunicipalityAges 18–70 - NCT05058183Recruiting
Testing shorter chemotherapy for early HER2 or triple‑negative breast cancer
This study looks at whether some people with stage 1 HER2-positive or “triple-negative” breast cancer may safely need less (de-escalated) chemotherapy after surgery. The goal is to keep the cancer risk low while reducing treatment intensity, using special blood testing over time.
LondonAges 18 years+ - NCT05976412Recruiting
Radiation to lymph nodes after surgery for higher-risk breast cancer
This trial looks at whether adding targeted radiation to lymph nodes after breast surgery can lower the chance of breast cancer coming back in people with higher-risk, node-negative disease. If you qualify, you may get a planned radiation approach designed for prevention, not treatment of spread.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06035016Recruiting
Pyrotinib and capecitabine after surgery for HER2+ breast cancer
This study tests whether taking pyrotinib (a daily pill) with capecitabine (another pill) after breast cancer surgery can help prevent HER2-positive early-stage breast cancer from coming back. It is for women who have already had their cancer removed and meet certain risk criteria.
Beijing, Beijing MunicipalityAges 18–75 - NCT00437879Recruiting
Ultrasound and MRI scans to track breast cancer response early
This study uses ultrasound and/or MRI scans to see how breast cancer responds early while you start “neoadjuvant” treatment (chemotherapy, with or without radiation before surgery). It may help doctors spot response sooner and better understand which imaging changes match treatment benefit.
Toronto, OntarioAges Any age - NCT06001086RecruitingPhase 2
Disitamab Vedotin plus Pyrotinib for HER2-positive early breast cancer
This trial tests a combination of two targeted drugs (Disitamab Vedotin and Pyrotinib) for people with HER2-positive early breast cancer. It aims to see if this treatment can improve outcomes before standard therapy.
Nanjing, JiangsuAges 18 years+ - NCT05159193RecruitingPhase 3
Pre-surgery chemotherapy and antibodies for HER2 breast cancer
This phase 3 trial compares two pre-surgery treatment plans for people with HER2-positive invasive breast cancer that has spread to nearby lymph nodes. It aims to see which plan works better to shrink the tumor before surgery and improve outcomes.
Guandong, GuangdongAges 18–70 - NCT05759546RecruitingPhase 2
Test a PARP and CDK4/6 medicine plus hormone therapy
This Phase 2 study tests whether combining a PARP inhibitor with a CDK4/6 inhibitor and hormone (endocrine) therapy can help people with advanced HR-positive, HER2-negative breast cancer. It’s for certain patients who have not yet had chemotherapy or targeted therapy for metastatic disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06268652RecruitingPhase 3
Personalized treatment guided by lab-grown tumor samples for advanced breast cancer
This trial tests whether using a personalized approach—growing your tumor cells in the lab to find the best treatment—can work better than standard treatments chosen by your doctor. It is for people with advanced breast cancer that has stopped responding to at least two previous treatments.
Guangzhou, None SelectedAges 18 years+
Hear when a new Breast Cancer Invasive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Breast Cancer Invasive trials by city
Studies with a site in or near these metro areas.
Breast Cancer Invasive trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for breast cancer invasive?
- Yes. Clin2 currently lists 717 recruiting breast cancer invasive studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer invasive trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer invasive trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.